It remains to be seen whether ECM components (such as the splice variants of fibronectin) or cellular antigens may represent equivalent targets for pharmacodelivery applications, or whether one class of targets may outperform the other as a result of better accessibility and a higher proximity to the tumor endothelium. The gene discussed is FN1; the disease is neoplasm.